Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

August 20, 2019

Study Completion Date

April 27, 2022

Conditions
Peanut Allergy
Interventions
BIOLOGICAL

Part A Viaskin Peanut 250 mcg

Viaskin Peanut 250 mcg, once daily

BIOLOGICAL

Part A Viaskin Peanut 100 mcg

Viaskin Peanut 100 mcg, once daily

BIOLOGICAL

Part A Placebo

Placebo patch, once daily

BIOLOGICAL

Part B Viaskin Peanut 250 mcg

Viaskin Peanut 250 mcg, once daily

BIOLOGICAL

Part B Placebo

Placebo patch, once daily

Trial Locations (51)

2031

Sydney Children's Hospital, Randwick

2145

The Children's Hospital at Westmead, Westmead

3015

Erasmus MC Sophia Children's Hospital, Rotterdam

3052

The Royal Children's Hospital, Parkville

4101

Queensland Children's Hospital, South Brisbane

5006

The Women's and children's hospital, North Adelaide

6009

Perth Children's Hospital, Nedlands

10029

Mount Sinai Medical Center, New York

10833

University of California School of Medicine, Los Angeles

14642

University of Rochester, Rochester

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's national Health System, Washington D.C.

21205

Johns Hopkins Hospital, Baltimore

27599

The University of North Carolina - Chapell Hill, Chapel Hill

30329

Emory University, Atlanta

35033

Universitatklinikum Giessen und Marburg, Marburg

37232

Vanderbilt University Medical Center, Nashville

38105

Le Bonheur Children's Hospital, Memphis

44195

Cleveland Clinic, Cleveland

46202

Riley Hospital for Children at Indiana University, Indianapolis

48106

University of Michigan Health System, Ann Arbor

54511

CHRU Nancy, Vandœuvre-lès-Nancy

57085

CHRU Metz-Thionville, Metz

59037

CHRU Lille, Lille

60590

Universitatsklinikum Frankfurt, Frankfurt

60611

Ann & Robert H. Lurie Children's Hospital of CHicago, Chicago

60637

The Universal of Chicago Medical Center, Chicago

72202

Arkansas Children's Hospital, Little Rock

75015

Hopital Necker, Paris

75235

Children's Medical Center of Dallas, Dallas

77030

Baylor College of Medicine - Texas Children's Hospital, Houston

78723

Dell Children's Medical Center, Austin

80045

Children's Hospital Colorado, Aurora

85719

University of Arizona Health Science, Tucson

92123

University of California, Rady Children's Hospital, San Diego

94158

University of California San Francisco, San Francisco

94305

Stanford University School of Medicine, Stanford

98115

ASTHMA, Inc., Seattle

02115

Boston Childrens' Hospital, Boston

V5H 3V4

British Columbia Children's Hospital, Vancouver

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C4

CHUM & CHU Sainte-Justine, Montreal

06200

Hopitaux Pediatriques de Nice, Nice

01307

Universitatsklinikum Carl Gustav Carus, Dresden

T12YE02

Cork University Hospital, Cork

SE17EH

Guy's and Saint Thomas' NHS Foundation Trust, London

W21NY

St.Mary's Hospital, London

M139WL

ROyal Manchester Children's Hospital, Manchester

S102TH

Sheffield Children's Hospital, Sheffield

SO166YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DBV Technologies

INDUSTRY

NCT03211247 - Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age | Biotech Hunter | Biotech Hunter